The company anticipates an addressable global market for progressive familial intrahepatic cholestasis of 2,500 patients, with initial plans to focus on around 100 physicians at 60 centers.

Reimbursement timelines in Italy and France for the treatments in question have been quicker than the average.

The subdued number of acquisitions of biotech by big pharma has more than one cause. The structural improvement of the process of drug discovery and development at big pharma is the main one.

Ruling keeps the principle of assignor estoppel in place, but restricts its use to situations where an inventor’s claims in court directly contradict those in the patent.